93 results about "Methylprednisolone" patented technology

The invention discloses a chemical synthesis method of methylpredmisolone. Fungi oxide is adopted as the initial material and methylpredmisolone is obtained after prevotella oxidation, bromine application, bromine removal, 6-bit methylenation, 6-bit methylation, ketal protection, 11- bit reduction, ketal hydrolization, 1 and 2 bit dehydrogenation, 21-bit iodine application, 21-bit permutation and 21-bit hydrolytic reaction. The flow of the synthesis method of the invention is reasonable, the yield rate and the purity of the intermediate products are high, the reaction condition is temperate, the by-products in the end product are few, the purity is high (reaching above 98 percent), the industrialization is easy to be realized, thereby the method has high application value.

The present invention provides improved devices and methods for minimizing and/or inhibiting restenosis and hyperplasia after intravascular intervention. In particular, the present invention provides luminal prostheses which allow for programmed and controlled methylprednisolone delivery with increased efficacy to selected locations within a patient's vasculature to inhibit restenosis. An intraluminal delivery prosthesis may comprise an expansible structure and means on or within the structure for releasing methylprednisolone into the body lumen to inhibit smooth muscle cell proliferation.

The invention relates to a drug composition for treating local inflammation, which uses methylprednisolone palmitate as an active composition. The drug composition consists of the methylprednisolone palmitate as the active composition and an inactive composition suitable for local injection, and is used for treating local inflammation of people or mammal through local injection.

The invention discloses a method for preparing 6 beta-methylprednisolone. The method comprises the following steps: taking 6-methyl epoxides as raw materials, after Grignard reaction, hydrolysis, elimination, generating 6 beta-methyl elimination, and then after dehydrogenation by fermentation, iodine putting, replacement, hydrolysis, preparation of liquid phase purification, obtaining 6 beta-methylprednisolone. A reaction formula is as follows: the formula is shown in the description, the 6 beta-methylprednisolone of the invention is a major synthetic impurity in methylprednisolone, separation and purification of the 6 beta-methylprednisolone have great significance on impurity analysis.

The present invention discloses the chemical synthesis process of methyl prednisoline. By using pregnenolone acetate as initial material, the present invention prepares methyl prednisoline through the steps of: epoxidation, mildew oxidation, place-11 reduction, place I and II dehydrogenation, place VI methylation and other reaction steps. The process of the present invention has mild reaction condition, high product purity, stable product quality, high product yield and low production cost, and is suitable for industrial production of methyl prednisoline.

The invention relates to a release speed-controllable type silk fibroin nanometer microsphere loading methylprednisolone and dexamethasone. The release speed-controllable type silk fibroin nanometer microsphere comprises silk fibroin with lower and higher release speeds; after the silk fibroin with lower and higher release speeds are dissolved, the molecular weight cutoff of the silk fibroin with lower drug release speed after dialysis is 12000 to 14000; the molecular weight cutoff of the silk fibroin with higher drug release speed is 100 to 500; the average particle size of the silk fibroin nanometer microsphere loading methylprednisolone and dexamethasone is 35 to 125nm. The release speed-controllable type silk fibroin nanometer microsphere loading methylprednisolone and dexamethasone has the advantages that the action times of methylprednisolone and dexamethasone at certain dosages can be effectively controlled according to the administration time after injury, the half-life period is controlled, the medicine effect is effectively realized under the condition of joint administration, the therapy effect is improved, and the toxic or side effect and poor reaction during single administration is reduced.

The invention discloses a pharmaceutical composition for the treatment of chronic obstructive pulmonary disease (COPD) and bronchial asthma, which is composed of a glucocorticoid, a bronchodilator and a pharmaceutically acceptable auxiliary material or carrier; the composition is a preparation for oral use. The glucocorticoid in the inventive pharmaceutical composition is selected from prednisone, prednisolone, methylprednisolone, betamethasone, decamethasone or hydrocortisone; the bronchodilator is selected from formoterol, clenbuterol, procaterol or theophylline. The inventive composition has better therapeutic effect on the COPD and the bronchial asthma than independent administration of two ingredients, and has synergistic effect. The composition has easily-available raw materials, inexpensive price and increased medicine taking compliance as well as plays a significant role in preventing and treating the COPD and the bronchial asthma of patients in vast rural areas and patients in low-income class of the city in China.

A pharmaceutical composition for treating allergic rhinitis comprises one or a plurality of kinds from methylprednisolone taken as active ingredient or pharmaceutically acceptable salt thereof or esterified matters thereof, and a pharmaceutical composition consisting of one or a plurality of inactive ingredients applicable to local action inside nasal cavity.

The invention provides an anti-cancer sustained-release agent co-carrying glucocorticoid and chemotherapeutic drugs and belongs to sustained-release injections. The anti-cancer sustained-release agent comprises sustained-release microspheres and a solvent, wherein, the sustained-release microspheres comprise anti-cancer active components and sustained-release auxiliary materials; and the solvent is a particular solvent containing a suspending agent. The glucocorticoid is selected from prednisolone, methylprednisolone, dexamethasone, betemethasone, triamcinolone acetonide or triamcinolone acetonide; the chemotherapeutic drugs are selected from phosphoinositide 3-kinase inhibitor, pyrimidine analogues and the like; the sustained-release auxiliary materials are biocompatible high-polymers, such as polylactic acid and the copolymers thereof, polyethylene glycol, carboxyl-terminated polylactic acid copolymers, polyfatty acid dimer-sebacic acid copolymers, poly(erucic acid dimer-sebacic acid), poly(fumaric-co-sebacic acid), polifeprosan and the like; and the suspending agent with the viscosity being 100cp to 3,000cp (at the temperature of 20 to 30 DEG C) is selected from sodium carboxymethyl cellulose and the like. The anti-cancer active components and the sustained-release microspheres can further be prepared into sustained-release implants which can effectively inhibit the growth of tumors, alleviate edema and improve the curative effects of radiotherapy and chemotherapy by intra-tumor or peri-tumor injection or placement.

The invention discloses a manufacturing method of 9, 11-deestering material, which comprises the following steps: adopting intermediate dehydrogenation as raw material; proceeding sulfur-esterifying reaction through dansyl chloride; diluting; filtering; obtaining the wet product; heating to reflux completely; complementing temperature-control water; adjusting reflux reaction at 109+-2 deg.c; diluting; filtering; drying to obtain methylprednisolone 9, 11- deestering material.

The invention discloses a methylprednisolone intermediate debrominated product and a preparation method thereof. According to the preparation method, a compound shown as a formula I is used as a raw material, and a dechlorination reaction, a bromination reaction, a debromination reaction and an oxidation reaction are sequentially performed to prepare a compound (debrominated substance) shown as aformula V. The preparation method has the advantages of short synthetic route, high yield, low cost and easily available raw materials, is suitable for industrial production, and has very high industrial value.

The invention discloses a method for preparing methylprednisolone. Hydrocortisone serves as the raw material, a hydroxyl group is protected through ketalation, six methyl groups are introduced through methylene reaction and catalytic hydrogenation, 6 alpha-methyl hydrocortisone is obtained through hydrolysis deprotection, and methylprednisolone is obtained through biodehydrogenation, wherein the equation is shown in the description. Hydrocortisone serves as the initial raw material, through five-step reaction, methylprednisolone is obtained with the total weight yield of 60% or above, reaction is simple, selectivity is good, and methylprednisolone is suitable for industrial production.

The invention provides a novel purpose of triptolide and a triptolide derivative. The triptolide can obviously inhibit the GFP fluorescent protein and P24 antigen rise effect in a phorbol ester activated lymphocyte model. When the concentration of the lymphocyte concentration is higher, the GFP positive cell percentage and the P24 antigen concentration are lower; the negative dosage-effect relationship exists. Even when the concentration of the methylprednisolone is as high as 400 uM, the inhibition effect cannot reach the inhibition effect of the triptolide with the concentration being 0.02 uM; the cell apoptosis proportion obviously exceeds the triptolide with the concentration being 0.02 uM. According to the principle, the triptolide inhibits the G0/G1 period cell proportion rise and S period cell proportion descending due to PMA; the cell period is promoted to be stopped in the unactivated state; the triptolide achieves the effect of inhibiting the lymphocyte cell proliferation and activation through regulating the cell period; meanwhile, the effect of inhibiting the virus replication is also achieved. The triptolide and the triptolide derivative can replace glucocorticoid analogues or can be combined with the glucocorticoid analogues to be used, and are used for treating and/or preventing lung injury diseases.

The invention discloses an oral sticking tablet used for treating canker sore of humans or mammals. The oral sticking tablet comprises a sticking layer containing an active ingredient and a water insoluble protective layer, wherein, a non-active ingredient contained in the sticking layer consists of a filling agent, an adhesive sustained-release agent and a lubricant which are applicable to tablets; the water insoluble protective layer is composed of polyacrylic acid resin and/or ethyl cellulose which can be used as protective coating, and a plasticizer; in addition, the active ingredient is methylprednisolone, or one or a combination of pharmaceutically acceptable esters.

The invention discloses a novel nanometer drug carrier loaded with methyllprednisolone. The novel nanometer drug carrier comprises methyllprednisolone and a carrier, wherein the carrier is an ibuprofen modified dextran nanometer microsphere, the particle diameter of the novel nanometer drug carrier loaded with methyllprednisolone is 120 to 160 nanometers, the preparation method of the novel nanometer drug carrier loaded with methyllprednisolone comprises two steps of synthesizing the ibuprofen modified dextran nanometer microsphere and preparing novel nanoparticles loaded with methyllprednisolone. The novel nanometer drug carrier loaded with methyllprednisolone disclosed by the invention has the advantages that the nanometer microsphere synthesized by ibuprofen modified dextran is taken as the carrier, so that methyllprednisolone can be effectively and targetedly delivered to injured parts, the half-life of methylprednisolone drugs can be effectively prolonged, and methyllprednisolone and ibuprofen can play a synergistic role on promotion of central nervous system injury repair.

The invention discloses a method for preparing dehydrogenated methyl-prednisone which adopts the medium product of the methyl-prednisone as the fermentation substrate and carries out biological dehydrogenation with the arthrobacter. Compared with the prior art, the invention adopts the medium product of the methyl-prednisone as the fermentation substrate, and substitutes the biological dehydrogenation with arthrobacter for the chemical dehydrogenation technique in the prior art, thereby increasing the harvest rate from 55 to 70-85 percent, decreasing greatly the cost, and improving the purity of the product to more than 97 percent, accomplishing the industrialized production of methyl-prednisone, and completely avoiding the residue of the deadly poison of SeO2 through the green technique.

The invention relates to a preparation method of a methylprednisolone key intermediate. According to the method, compound I serving as reactant is subjected to cyanohydrination reaction, protective reaction, low-temperature reaction and hydrolysis reaction to prepare the methylprednisolone key intermediate, namely, the compound V. The preparation method is low in production cost and high in yield, and the reaction line is as shown in the specification.

The invention discloses a methylprednisolone preparation method, wherein a compound represented by a formula 1 is used as a starting material, and biotransformation, oxidation, esterification, reduction and hydrolysis are sequentially performed to obtain the methylprednisolone.

The invention discloses methylprednisolone-loading nanoparticles which consist of methylprednisolone and a carrier at a weight ratio of 1:(2-20), wherein the carrier is ibuprofen-modified ibuprofen and the grain size of the methylprednisolone-loading nanoparticles is 70-400nm. The invention further discloses a preparation method and application of the nanoparticles. The methylprednisolone-loading nanoparticles disclosed by the invention can be used for effectively transferring methylprednisolone to the injured part in a targeting manner, and have a very strong methylprednisolone slow-release function, so that side effects caused by high dosage and toxicity of methylprednisolone are avoided.

The invention provides a production method of a methylprednisolone dehydrogenate. The production method of the methylprednisolone dehydrogenate comprises the following steps: A) adding water into a methylprednisolone Grignard substance, and pulping to obtain slurry; and B) biologically converting the methylprednisolone Grignard substance in the slurry into a methylprednisolone dehydrogenized substance by using arthrobacter simplex. According to the production method, no organic solvent is used, and the toxic effect on microorganisms is small during biotransformation; according to the method, the methylprednisolone Grignard substance is added with water and pulped into slurry, so that the feeding concentration and the substrate conversion rate of the methylprednisolone Grignard substance are greatly improved, the yield of a methylprednisolone dehydrogenized substance product is high, and the method is particularly beneficial to industrial production of the methylprednisolone dehydrogenized substance.

The invention relates to a method for amelioration of neurological outcome in humans with spinal cord damage by administration of ganglioside GM1. Another object of the present invention is to provide combination therapies for the treatment of spinal cord damage comprised of the administration of the ganglioside GM1 and other drugs which have therapeutical benefit in patients with spinal cord damage, preferably methylprednisolone.